Literature DB >> 6083740

A classification of human urothelial cells propagated in vitro.

B Christensen, J Kieler, M Vilien, P Don, C Y Wang, H Wolf.   

Abstract

Human urothelial cell lines of non-malignant and malignant origin were classified into three grades of transformation, i.e. TGr I, TGr II, and TGr III, which differ from primary and early cultures of normal bladder mucosa (TGr 0) by growth in the absence of fibroblasts, prolonged survival, increasing chromosomal abnormalities, and antigenic modifications. Non-malignant pure epithelial cell lines with a prolonged, but finite life span (18-38 passager in vitro) were classified as TGr I. These cells were characterized by chromosomal counts showing a considerable variation but with a near-diploid mode and a smaller size but otherwise normal morphology. TGr II cells differed from TGr I by infinite growth transformation and wide morphological variability. TGr III cells were above all characterized by their ability to produce tumors in nude mice and to invade and destroy fragments of embryonic heart in vitro. These immortalized cells were small with a large nucleus and a uniform polygonal shape. Chromosomal counts showed pronounced aneuploidy with an increased number of chromosomes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6083740

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  17 in total

1.  Towards quantitative mRNA analysis in paraffin-embedded tissues using real-time reverse transcriptase-polymerase chain reaction: a methodological study on lymph nodes from melanoma patients.

Authors:  Helene Nortvig Abrahamsen; Torben Steiniche; Ebba Nexo; Stephen J Hamilton-Dutoit; Boe Sandahl Sorensen
Journal:  J Mol Diagn       Date:  2003-02       Impact factor: 5.568

2.  Recombinant human interferon gamma exerts an anti-proliferative effect and modulates the expression of human leukocyte antigens A,B,C and DR in human urothelial cell lines.

Authors:  S S Ottesen; V Ahrenkiel; J Kieler
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Wheat germ agglutinin binding sites on human urothelial cells of different grades of transformation.

Authors:  D Dus; M Ugorski; W Gorczyca; C Radzikowski
Journal:  Glycoconj J       Date:  1989       Impact factor: 2.916

4.  Spreading of cells on various substrates evaluated by Fourier analysis of shape.

Authors:  J Kieler; K Skubis; W Grzesik; P Strojny; J Wisniewski; A Dziedzic-Goclawska
Journal:  Histochemistry       Date:  1989

5.  Pyruvate kinase inhibited by L-cysteine as a marker of tumorigenic human urothelial cell lines.

Authors:  M Gumińska; M B Stachurska; B Christensen; V Tromholt; J Kieler; C Radzikowski; D Duś
Journal:  Experientia       Date:  1989-06-15

6.  Correlation between classification of human urothelial cell lines and HLA-A,B,C expression.

Authors:  S S Ottesen; V Tromholt; J Kieler
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Fourier analysis of the cell shape of paired human urothelial cell lines of the same origin but of different grades of transformation.

Authors:  K Ostrowski; A Dziedzic-Goclawska; P Strojny; W Grzesik; J Kieler; B Christensen; M Mareel
Journal:  Histochemistry       Date:  1986

Review 8.  Invasiveness of transformed bladder epithelial cells.

Authors:  J F Kieler
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

9.  Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis.

Authors:  Lise Mette Gjerdrum; Boe Sandahl Sorensen; Eigil Kjeldsen; Flemming Brandt Sorensen; Ebba Nexo; Stephen Hamilton-Dutoit
Journal:  J Mol Diagn       Date:  2004-02       Impact factor: 5.568

10.  Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma.

Authors:  G G Hermann; P F Geertsen; H von der Maase; J Zeuthen
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.